PLAG1 antibody
- Known as:
- PLAG1 (anti-)
- Catalog number:
- orb101852
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Biorbyt biorb
- Gene target:
- PLAG1 antibody
Related genes to: PLAG1 antibody
- Gene:
- PLAG1 NIH gene
- Name:
- PLAG1 zinc finger
- Previous symbol:
- -
- Synonyms:
- ZNF912
- Chromosome:
- 8q12.1
- Locus Type:
- gene with protein product
- Date approved:
- 1998-02-11
- Date modifiied:
- 2016-11-01
Related products to: PLAG1 antibody
Related articles to: PLAG1 antibody
- Lipoblastoma is a benign tumor of adipocytic differentiation originating from embryonal white fat that is commonly described in young children, with rare cases arising in adults. gene (8q11-13) rearrangement is a characteristic feature of lipoblastoma. However, gene rearrangement has also been reported in a few cases of lipoblastoma, with the gene fusion partners reported thus far being , and genes. Herein, we report an -rearranged lipoblastoma arising in the chin of a 51-year-old female with a novel gene fusion partner, the gene, that has not been previously described in lipoblastomas. Our case adds to the growing pool of gene fusion partners of -rearranged lipoblastomas and expands the molecular spectrum of lipoblastomas in general beyond the previously described gene rearrangements, thereby suggesting that lipoblastomas may be more molecularly heterogeneous than previously appreciated. - Source: PubMed
Publication date: 2026/08/27
Naous RanaVictor Aaron - GPNMB is a lysosomal transmembrane protein that has emerged as a diagnostic marker for tumours driven by the microphthalmia-associated transcription factor family (TFE3 and TFEB) and mTOR pathway activation. Diffuse, moderate-to-strong GPNMB positivity has been proposed as a surrogate marker for both translocation-driven and mTOR pathway-activated neoplasms, including PEComas. This study investigated the diagnostic utility of GPNMB immunohistochemistry in differentiating uterine PEComas from common morphological mimics among uterine mesenchymal tumours. - Source: PubMed
Publication date: 2026/09/25
Skopal JosefŠvajdler MariánPtáková NikolaVaněček TomášMichal MichaelGettse PolinaPresl JiříKormunda StanislavNovotný JanDundr PavelMichal MichalMichalová Květoslava - Myoepithelial carcinoma (MECA) represents a rare malignant neoplasm accounting for less than 2% of all salivary tumors, with recurrent PLAG1 rearrangements comprising its predominant underlying molecular aberration. - Source: PubMed
Publication date: 2026/09/22
Argyris Prokopios PTjota Melissa YLingen Mark WCipriani Nicole A - PLAG1 immunohistochemistry and FISH were essential for diagnosis of extra-uterine myxoid leiomyosarcoma and should be considered in myxoid intra-abdominal tumors, especially in patients with previous uterine surgery. - Source: PubMed
Publication date: 2026/09/16
Hsieh Cheng-EnWu Po-HsuanSu Chang-WeiMa Yu-ChunHuang Hsuan-Ying - Salivary gland neoplasms (SGNs) represent a diverse group of benign and malignant tumors characterized by distinct genetic abnormalities that contribute to their pathogenesis and variable clinical behavior. This review synthesizes current evidence on the molecular alterations underlying SGNs and highlights emerging therapeutic targets with translational potential. A comprehensive literature search was conducted across PubMed, Google Scholar, Cochrane, and SCOPUS for studies published between 1990 and 2025, focusing on genetic aberrations, oncogenic fusions, and targeted treatment strategies. Data reveal that small molecule inhibitors and other targeted agents may offer promising alternatives to conventional chemotherapy. For instance, pleomorphic adenomas often have PLAG1 overexpression and FGFR1 fusions, activating the IGF and WNT signaling pathways; linsitinib, a dual IGF1R and tyrosine kinase inhibitor, has demonstrated antitumor activity in other malignancies and may hold potential in this context. Similarly, alterations in EGFR, HER2, and PI3K pathways across multiple salivary tumor subtypes highlight opportunities for small molecular inhibitor therapy. However, current data remain limited, and therapeutic applications are largely extrapolated from other cancers. Further research is needed to validate these findings in clinical trials. Overall, integrating molecular diagnostics with pathway-specific targeted therapies may enhance outcomes and expand treatment options for patients with SGNs. - Source: PubMed
Publication date: 2026/09/15
Kota SharwaniSmith Richard V